Fluoroquinolones (FQs) are highly potent bactericidal antibiotics with broad-spectrum
activity against Gram-negative/positive bacteria. The Food and Drug Administration (FDA) …

Antibacterial fluoroquinolones (FQs) are frequently used in treating infections. However, the
value of FQs is debatable due to their association with severe adverse effects (AEs). The …

In the last decade, several third and fourth generation fluoroquinolones (FQs) have been
approved for clinical use. These new agents exhibit a more potent and broader-spectrum …

The Food and Drug Administration (FDA) safety review revealed that the use of
fluoroquinolones (FQs) is linked with disabling and potentially permanent serious adverse …

Introduction Fluoroquinolone (FQ) antibiotics were approved in 1986 for treatment of urinary
tract infections, sinusitis, and bronchitis. Numerous putative FQ-associated adverse events …

Reactions of the gastrointestinal tract and the central nervous system are the most often
observed adverse effects during therapy with fluoroquinolones. Pathogenesis of the …

For 2 decades fluoroquinolones have been found to be generally well-tolerated and safe.
Adverse events may be inherent to the class or influenced by structural modifications. The …

BACKGROUND: Premarketing trials showed the fluoroquinolone agents to have a favorable
side-effect profile, with treatment-related adverse events comprising gastrointestinal, central …

Fluoroquinolones are highly effective antibiotics with many advantageous pharmacokinetic
properties including high oral bioavailability, large volume of distribution, and broad …

The fluoroquinolone class of antibacterial agents are among the most frequently prescribed
drugs, with utility in a broad range of bacterial infections. Although very useful agents, the …